Department of Pharmacology, Faculty of Medicine of Ribeirão Preto University of São Paulo, Avenida Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM380 PR445, 86051-990 Londrina, PR, Brazil Biology Institute, State University of Campinas, UNICAMP, Campinas, São Paulo, Brazil.
Pain. 2010 Nov;151(2):506-515. doi: 10.1016/j.pain.2010.08.014. Epub 2010 Sep 1.
Through activation of the A1 adenosine receptors (A1Rs) at both the central and peripheral level, adenosine produces antinociception in a wide range of tests. However, the mechanisms involved in the peripheral effect are still not fully understood. Therefore, the mechanisms by which peripheral activation of A1Rs reduces inflammatory hypernociception (a decrease in the nociceptive threshold) were addressed in the present study. Immunofluorescence of rat dorsal root ganglion revealed significant expression of A1Rs in primary sensory neurons associated with nociceptive pathways. Functionally, peripheral activation of A1Rs reduced inflammatory hypernociception because intraplantar (i.pl.) administration of an A1R antagonist (DPCPX) enhanced carrageenan-induced hypernociception. On the other hand, local (paw) administration of CPA (a selective A1R agonist) reversed mechanical hypernociception induced by carrageenan or by the directly acting hypernociceptive mediator prostaglandin E(2) (PGE(2)). Down-regulation of A1Rs expression in primary nociceptive neurons by intrathecal treatment with antisense oligodeoxinucleotides significantly reduced peripheral antinociceptive action of CPA. Direct blockade of PGE(2) inflammatory hypernociception by the activation of A1Rs depends on the nitric oxide/cGMP/Protein Kinase G/KATP signaling pathway because the peripheral antinociceptive effect of CPA was prevented by pretreatment with inhibitors of neuronal nitric oxide synthase (N-propyl-l-arginine), guanylyl cyclase (ODQ), and Protein Kinase G (KT5823) as well as with a KATP blocker (glibenclamide). However, this effect of CPA was not reduced by naloxone, excluding the participation of endogenous opioids. These results suggest that the peripheral activation of A1R plays a role in the regulation of inflammatory hypernociception by a mechanism that involves the NO/cGMP/PKG/KATP intracellular signaling pathway.
通过在中枢和外周水平激活 A1 腺苷受体 (A1R),腺苷在广泛的测试中产生镇痛作用。然而,外周效应的机制仍不完全清楚。因此,本研究旨在探讨外周激活 A1R 如何减少炎症性痛觉过敏(痛觉阈值降低)。大鼠背根神经节的免疫荧光显示,与痛觉通路相关的初级感觉神经元中存在显著的 A1R 表达。功能上,外周激活 A1R 可减轻炎症性痛觉过敏,因为足底(i.pl.)给予 A1R 拮抗剂(DPCPX)可增强角叉菜胶诱导的痛觉过敏。另一方面,局部(爪子)给予 CPA(一种选择性 A1R 激动剂)可逆转由角叉菜胶或直接作用的致痛性介质前列腺素 E2 (PGE2) 引起的机械性痛觉过敏。鞘内给予反义寡核苷酸下调初级伤害感受神经元中的 A1R 表达,显著降低了 CPA 的外周镇痛作用。通过激活 A1R 直接阻断 PGE2 炎症性痛觉过敏取决于一氧化氮/cGMP/蛋白激酶 G/KATP 信号通路,因为 CPA 的外周镇痛作用可被神经元型一氧化氮合酶(N-丙基-L-精氨酸)、鸟苷酸环化酶(ODQ)和蛋白激酶 G(KT5823)的抑制剂以及 KATP 阻断剂(格列本脲)预处理所阻止。然而,CPA 的这种作用不会被纳洛酮降低,排除了内源性阿片类物质的参与。这些结果表明,外周激活 A1R 通过涉及 NO/cGMP/PKG/KATP 细胞内信号通路的机制在调节炎症性痛觉过敏中发挥作用。